阿达木单抗、依那西普与甲氨蝶呤治疗银屑病的真实世界比较
基于瑞典斯德哥尔摩DermaReg登记数据,共分析524例患者、727个治疗疗程,比较阿达木单抗(ADA)、依那西普(ETN)与甲氨蝶呤(MTX)在维持治疗期间的药物留存及PASI、DLQI。校正混杂后,ADA较MTX药物留存更好、平均PASI与DLQI更低;ETN与MTX比较结果不一致,药物留存无显著差异但平均PASI较低。
要点
- 真实世界中ADA较MTX药物留存更好且PASI、DLQI更低。
- ETN较MTX药物留存无显著差异,但维持期平均PASI较低。
- ETN与MTX的相对有效性尚不明确,需注意混杂控制。
核心结论
- 在临床实践中阿达木单抗优于甲氨蝶呤,而依那西普与甲氨蝶呤的相对有效性较不明确。
- 研究同时强调有效性分析中适当控制混杂因素的重要性。
研究设计与样本
- 基于瑞典斯德哥尔摩地区登记库DermaReg的真实世界数据分析。
- 共524例患者启动727个ADA、ETN或MTX治疗疗程。
- 估计维持治疗期间的药物留存及平均PASI与DLQI。
主要发现
- 校正混杂后,ADA组较MTX组药物留存更好(HR:0.67;P = 0.003)。
- ADA组维持治疗期间平均PASI较MTX低2.0(P < 0.001),平均DLQI低0.9(P < 0.001)。
- ETN较MTX药物留存无显著差异(HR 1.23;P = 0.082)。
- ETN组维持治疗期间平均PASI较MTX低0.7(P = 0.006)。
临床怎么用
- 在真实临床中选择一线系统性治疗时,ADA较MTX在药物留存与PASI、DLQI方面表现更优。
- ETN与MTX的取舍需结合个体情况,因两者相对有效性证据不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The advent of biosimilars may render etanercept (ETN) and adalimumab (ADA) viable alternatives to methotrexate (MTX) as first-line systemics in psoriasis. However, real-world relative effectiveness data comparing ADA and ETN to MTX are limited. OBJECTIVE: To estimate the relative effectiveness of ADA and ETN compared to MTX. METHODS: We analysed data from DermaReg, a regional register in Stockholm, Sweden, to estimate drug survival and mean Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) during maintenance treatment. RESULTS: A total of 524 patients initiated 727 treatment episodes with ADA, ETN or MTX. After adjusting for confounders, patients treated with ADA had better drug survival (HR: 0.67; P = 0.003), lower mean PASI (-2.0; P < 0.001) and lower mean DLQI (-0.9; P < 0.001) during maintenance treatment compared to patients treated with MTX. The results for ETN compared to MTX were mixed. After adjusting for confounding, there was no significant difference in drug survival (HR 1.23; P = 0.082), but patients on ETN had lower mean PASI (-0.7; P = 0.006) during maintenance treatment. CONCLUSION: Adalimumab is superior to MTX in clinical practice whereas the relative effectiveness between ETN and MTX is less clear. This study also highlights the importance of appropriate confounding control in effectiveness analysis.
引用
- Svedbom A, Ståhle M. Real-world comparative effectiveness of adalimumab, etanercept and methotrexate: a Swedish register analysis. J Eur Acad Dermatol Venereol. 2019. PMID: 31568598. doi:10.1111/jdv.15978
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。